Ropeginterferon alfa-2b (Besremi) for PV — 1L cytoreductive

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ROPEGINTERFERON-ALFA-2B` `DRUG-ASPIRIN`

ID	`REG-ROPEGINTERFERON-PV`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MPN-2015` `SRC-NCCN-MPN-2025` `SRC-PROUD-PV-GISSLINGER-2020`

Notes

First-line cytoreductive for newly-dx PV in HU-naive low-risk young patients (<60, no thrombosis history). Disease-modifying potential — JAK2-V617F allele burden reduction. Pegylated long- acting (q2wk dosing, vs q1wk for standard PEG-IFNa-2a). STUB — pending Co-Lead sign-off.

Used By

Indication

IND-PV-1L-ROPEGINTERFERON - IND-PV-1L-ROPEGINTERFERON
IND-PV-PREGNANCY-PEG-IFN - IND-PV-PREGNANCY-PEG-IFN